Fundraising FoxLogos — Full Portfolio
4 tracked investments · listed companies and verified rows first
ALX Oncology develops therapies for cancer treatment, operating in the biotechnology and medical technology sectors.
BiotechHealthtechMedical Devices
Corey Goodman(Chairman)inJason Lettmann(Chief Executive Officer)in
Co-investorsLightstone Venturesage1Foresite CapitalHBM Healthcare InvestmentsHBM PartnersvenBio Partners+1 more
Nkarta is a biotech company developing allogeneic CAR NK cell therapies for autoimmune diseases, aiming to offer safer and more accessible alternatives to autologous CAR-T treatments.
BiotechHealthtechSouth San Francisco, US
Paul Hastings(Executive Officer, Director)inPaul H.inMatthew Plunkett(Executive Officer)inPaul J. Hastings(Chief Executive Officer)in
BoardMichael Dybbs(Director)Jill Carroll(Director)in
Co-investorsNew Enterprise Associates (NEA)RA CapitalSamsara BioCapitalSR One Capital ManagementAmgen VenturesNorwest Venture Partners+1 more
Olema is a clinical-stage biopharmaceutical company developing novel therapies for metastatic breast cancer and other endocrine-driven cancers, targeting nuclear receptors and mechanisms of acquired resistance.
BiotechHealthtechSan Francisco, US
Cyrus L. Harmon, Ph.D.(Director)Cyrus Harmon(Executive Officer, Director)inCyrus L. Harmon(Director)inDavid C. Myles, Ph.D.(Executive Officer)Sean Bohen, M.D., Ph.D.(Executive Officer, Director)Naseem Zojwalla, M.D.(Executive Officer)in
Co-investorsAvoro Capital AdvisorsBain Capital Life SciencesForesite CapitalLightspeed Venture PartnersRA CapitalBiotechnology Value Fund+1 more
NiKang Therapeutics is a clinical-stage biotechnology company developing small molecule drugs for cancer, using structure-based drug design against targets such as HIF2α, CDK2, KRAS, and SHP2.
BiotechHealthtechWilmington, CN
Yan Lou(Founder)inZhenhai Gao(President, CEO, and Secretary)Hong (Kelsey) Chen(Chief Financial Officer)
BoardGary Yeung(Director)Ting Jia(Director)Roderick Wong(Director)
Co-investorsEcoR1 CapitalHBM Healthcare InvestmentsHBM PartnersLAVLilly Asia VenturesRA Capital+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.